Extended Data Fig. 3: Relationship between MPR, histology, and TMB.
(a) Pathologic response by mutation status (n = 85). TMB showed a positive but not significant trend with pathologic response in non-squamous (R = 0.28; P = 0.05) and squamous (R = 0.23; P = 0.22) tumors. KEAP1 mutations were not significantly associated with pathologic response in either non-squamous (P = 0.46) or squamous tumors (P = 0.98). KRAS and STK11 mutations were found only in non-squamous tumors, where mutations in STK11 were found to significantly associate with pathologic response (P = 0.01), and mutations in KRAS were not (P = 0.87). (b) Pathologic response by the overlapping mutational status of KRAS and STK11 in patients with non-squamous NSCLC (n = 78). The maximum and minimum values of the boxes denote the IQR. The line within the IQR denotes the median. The extremities of the dashed lines represent the 5th to 95th percentiles. *TMB was only determined for the subset of patients with ES data from baseline and/or surgery with tumor purity ≥15%. P values for TMB in Panel a were determined via linear correlation test (Pearson). P values for mutation status in Panels a and b were determined via two-sided Wilcoxon rank sum test. ES, exome sequencing; IQR, interquartile range; KEAP1, Kelch-like ECH-associated protein 1; KRAS, Kirsten rat sarcoma viral oncogene homolog; MPR, major pathologic response; NS, non-significant; NSCLC, non-small cell lung cancer; STK11, serine/threonine kinase 11; TMB, tumor mutational burden.
